If you've looked at a compounded ED medication and seen "apomorphine" on the ingredient list, you're looking at one of the most interesting and least understood components in modern ED formulations. Here's what it actually does.
What Apomorphine Is
Despite the name, apomorphine has nothing to do with morphine. It's a dopamine receptor agonist — it directly stimulates D1 and D2 dopamine receptors in the brain. Dopamine is the neurotransmitter most closely associated with desire, reward, and sexual arousal.
In ED treatment, apomorphine works at the hypothalamic level, enhancing the central arousal signal that initiates the erectile cascade. Think of it as turning up the brain's "go" signal, while PDE5 inhibitors keep the downstream blood vessels open once the signal arrives.
The History
Apomorphine was approved in Europe as a standalone ED medication (Uprima/Ixense) in the early 2000s — a sublingual tablet that dissolved under the tongue in 10–20 minutes. It never took off commercially. The efficacy was modest compared to PDE5 inhibitors (30–50% response rate vs. 65–80%), and nausea was a significant side effect at effective doses.
Uprima was eventually withdrawn from most markets. But the mechanism remained sound — it just wasn't competitive as monotherapy. The revival of apomorphine in modern ED treatment is as a combination ingredient, where a lower dose provides additive benefit alongside a PDE5 inhibitor without the nausea issues of the higher monotherapy doses.
Evidence for the Combination
The evidence for apomorphine combined with PDE5 inhibitors is limited but logical:
Mechanistic rationale: Strong. PDE5 inhibitors enhance peripheral blood flow but don't affect central arousal. Apomorphine enhances central arousal but doesn't directly affect blood flow. The combination addresses both limbs of erectile physiology. This complementary mechanism is well-supported by pharmacology.
Clinical data: Limited. Small studies and case series report improved outcomes with the combination versus PDE5 monotherapy, but large randomized controlled trials are lacking. The evidence is promising but not definitive.
Real-world use: Widespread in the compounded ED space, with many telehealth providers reporting positive patient outcomes. This is a softer form of evidence than clinical trials but not irrelevant.
Side Effects at Combination Doses
At the lower doses used in combination formulations (typically 2–4mg sublingual, compared to 4–6mg in the original monotherapy products), nausea is significantly less common — though not eliminated. Other potential effects include yawning (yes, that's a real side effect of dopamine agonists), dizziness, and occasionally somnolence.
The most important safety consideration: apomorphine can lower blood pressure, and when combined with a PDE5 inhibitor (which also lowers blood pressure), the cumulative drop may be more pronounced. Stay hydrated, avoid excessive alcohol, and stand up slowly after taking the combination.
Is It Worth the Upcharge?
A compounded troche containing tadalafil + apomorphine typically costs more than generic tadalafil alone. Whether the additional ingredient justifies the additional cost depends on your situation:
Worth considering if: You respond partially to PDE5 inhibitors and feel that desire or arousal is a contributing factor, not just blood flow. The apomorphine component may provide the additional push you need.
Probably not worth it if: You respond fully to PDE5 inhibitors, or your ED is primarily vascular/mechanical. In that case, you're paying extra for an ingredient that targets a pathway that isn't your bottleneck.